Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,600 | -12,959 | -14,287 | -112,662 | -37,127 |
| Depreciation Amortization | 22 | 22 | 7 | 186 | 272 |
| Accounts payable and accrued liabilities | -647 | -314 | 828 | -859 | -2,731 |
| Other Working Capital | -929 | -1,055 | 1,619 | -1,759 | -8,327 |
| Other Operating Activity | 1,259 | 749 | -344 | 90,082 | 10,227 |
| Operating Cash Flow | $-12,894 | $-13,557 | $-12,178 | $-25,011 | $-37,686 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -16 | -93 | N/A | N/A |
| Investing Cash Flow | $0 | $-16 | $-93 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 5,048 | 16,140 | 5,789 | 683 | 1,747 |
| Other Financing Activity | -408 | -1,319 | -649 | 0 | 0 |
| Financing Cash Flow | $4,640 | $14,822 | $5,140 | $683 | $1,747 |
| Exchange Rate Effect | 5 | -7 | -8 | 39 | -3 |
| Beginning Cash Position | 22,890 | 21,648 | 28,787 | 53,076 | 89,018 |
| End Cash Position | 14,641 | 22,890 | 21,648 | 28,787 | 53,076 |
| Net Cash Flow | $-8,254 | $1,250 | $-7,139 | $-24,289 | $-35,942 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,894 | -13,557 | -12,178 | -25,011 | -37,686 |
| Capital Expenditure | 0 | -16 | -93 | N/A | N/A |
| Free Cash Flow | -12,894 | -13,572 | -12,271 | -25,011 | -37,686 |